


Anti TB Drugs



First Line drugs (primary)

Second Line drugs (secondary)



- Indication :
- 1- Resistance to First Line drugs
 - 2- Failure of clinical response to conventional therapy
 - 3- occurrence of serious treatment-limiting adverse drug reactions
 - 4- Availability of expert guidance to manage toxic effects.

There are about 9 million new cases annually.
TB killed 1.7 million people worldwide in 2006.

Isoniazid (INH)

most active

MOA:

- *Prodrug, activated by KatG (mycobacterial catalase-peroxidase).
- Blocks mycolic acid synthesis, disrupting mycobacterial cell wall synthesis and leading to a bactericidal effect in actively growing Mycobacterium tuberculosis cells.

Adverse Effect :

- Hepatitis (1%): anorexia, nausea, vomiting, jaundice, pain, and in severe cases lead to death // Depend on with age, alcohol use, and pregnancy.
 - Neuropathy (10–20%): More in slow acetylators, and in patients have malnutrition, alcoholism, DM, AIDS, or uremia // cause: due to pyridoxine deficiency.
 - Neurotoxicity: memory loss, psychosis, and seizures.
- Other: Hematologic, tinnitus, GIT, and drug interactions.

Notes:

- Small molecule, water-soluble, and structurally related to pyridoxine.
- TB lesions typically contain more than 10^8 bacilli.
- Resistance likelihood:
- Monotherapy: 1 in 10^6
- Combination therapy: Reduces resistance to 1 in 10^{12}
- Readily absorbed and widely distributed, including penetration into macrophages.
- Metabolized by acetylation: Slow and fast acetylators.

Rifampin / Rifadin / Rimactane

Derived from *Streptomyces mediterranei*.

- MOA:**
- Binds to the beta subunit of bacterial RNA polymerase and inhibiting RNA synthesis.
 - Bactericidal.

Indications:

- Tuberculosis (TB).
- Leprosy.
- Meningococcal carrier state.
- Prophylaxis for *Haemophilus influenzae*.
- Serious staphylococcal infections, including osteomyelitis and valve endocarditis.

Toxicity:

- Imparts harmless orange color to secretions (tears, urine, sweat).
- Rashes.
- Hepatitis.
- Flu-like syndrome.

- Liver enzyme inducer: Can lower serum levels of many drugs.

Notes:

- Active against Gram (+), Gram (-) bacteria, mycobacteria, enterococci, and chlamydia.
- Well absorbed, highly protein-bound, and widely distributed.
- Hepatic metabolism and exhibits enterohepatic recirculation.

First-Line drugs

Ethambutol

Streptomycin

Primary - second line - primary anti TB agent

Uses:

- Tuberculosis.
- Plague.
- Tularemias حمى الأرانبي (an infectious disease caused by *Francisella tularensis*) (symptoms: fever, skin, large lymph nodes).
- Brucellosis (malta fever).
- Endocarditis.

Adverse Effect:

- Allergy: Fever, rashes, and pain following intramuscular injection.
- Vestibular toxicity: Irreversible.
- Nephrotoxicity.

Pyrazinamide

Recommended Duration of Therapy

Regimen (in Approximate Order of Preference)	Duration in Months
Isoniazid, rifampin, pyrazinamide	6
Isoniazid, rifampin	9
Rifampin, ethambutol, pyrazinamide	6
Rifampin, ethambutol	12
Isoniazid, ethambutol	18
All others	≥24

Ethionamide

* Related to Isoniazid

- oral
- Good distribution.

MOA: Blocks mycolic acid synthesis

Adverse effect: Poorly tolerated:

- 1- Severe gastrointestinal (GIT) irritation.
- 2- Neurotoxicity.
- 3- Hepatotoxicity.

Capreomycin

Injectable

MOA: Peptide protein synthesis inhibitor

Adverse effect:

- 1- Nephrotoxicity.
- 2- Ototoxicity.
- 3- Local pain and sterile abscesses may occur.

Cycloserine

MOA: Inhibits cell wall synthesis

Adverse Effect:

- 1- Peripheral neuropathy.
- 2- CNS toxicity, including depression and psychotic reactions

Para-Amino-Salicylic Acid (PAS)

- Well absorbed.
- Dose: 8-12 gm/day.
- Widely distributed, except in the CNS.
- Excreted in urine.

MOA: Folate synthesis antagonist

Adverse effect:

- 1- GI toxicity.
- 2- Hypersensitivity reactions.
- 3- Crystalluria.

Linezolid

Drug for last resort (الدواء للأخير)

Effective against multidrug-resistant strains

AE:

- 1- Bone marrow suppression.
- 2- Irreversible peripheral and optic neuropathy.

Second-line drugs

Rifabutin & Rifapentine

- Related to Rifampin.
- Both Rifabutin and Rifapentine are inducers of CYP P450 enzymes, though Rifabutin is a less potent inducer.
- Rifabutin is used in place of Rifampin for the treatment of tuberculosis (TB) in HIV-infected patients receiving protease inhibitors or non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz).
- Inhibit bacterial RNA polymerase

Amikacin


- Active against: 1- multidrug-resistant strains.
- 2- atypical mycobacteria.

Fluoroquinolones

- * An important addition to TB treatment
- * Resistance develops rapidly if used alone

Atypical Mycobacteria (Nontuberculus Mycobacteria)

- Account for 10% of clinical isolates.
- Exhibit distinctive laboratory characteristics.
- Found in the environment.
- Not transmissible from person to person.
- Less susceptible to drugs.



- * Drugs :
- 1- Erythromycin
 - 2- Sulphonamides
 - 3- Tetracycline

* important and common cause disseminated TB in late stages of AIDS.

* Drugs : Azithromycin / clarithromycin + Ethambutol + ciprofloxacin

- 5% of these cases are drug-resistant tuberculosis.
- Mortality rates:
- 49% for extensively drug-resistant TB (XDR-TB).
- 19% for multidrug-resistant TB (MDR-TB).

Drug-Resistant TB (3)

Mono-resistant	Resistant to any one TB treatment drug
Poly-resistant	Resistant to at least any 2 TB drugs (but not both isoniazid and rifampin)
Multidrug resistant (MDR TB)	Resistant to at least isoniazid and rifampin, the 2 best first-line TB treatment drugs
Extensively drug resistant (XDR TB)	Resistant to isoniazid and rifampin, PLUS resistant to any fluoroquinolone AND at least 1 of the 3 injectable second-line drugs (e.g., amikacin, kanamycin, or capreomycin)